Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Study to Evaluate the Dose, Safety and Tolerability of an Intraperitoneal α-emitting Radionuclide Therapy (Radspherin) in Subjects With Peritoneal Carcinomatosis From Colorectal Carcinoma Following Hyperthermic Intraperitoneal Chemotherapy

Next Previous
Trial Profile

A Phase 1 Study to Evaluate the Dose, Safety and Tolerability of an Intraperitoneal α-emitting Radionuclide Therapy (Radspherin) in Subjects With Peritoneal Carcinomatosis From Colorectal Carcinoma Following Hyperthermic Intraperitoneal Chemotherapy

Status: Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 30 Jun 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Radspherin (Primary)
  • Indications Carcinoma; Colorectal cancer; Ovarian cancer; Peritoneal cancer
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Sponsors Oncoinvent

Most Recent Events

  • 18 Jun 2025 According to an Oncoinvent media release, positive final data and topline results from this study of Radspherin in patients with peritoneal metastases originating from colorectal cancer, will be presented in a webcast to be held on June 18th 2025 at 13:00 CEST.
  • 18 Jun 2025 According to an Oncoinvent media release, additional results will be published upon completion of the full dataset analysis.
  • 18 Jun 2025 Results published in the Oncoinvent Media Release

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top